Braking bad: blockade of inhibitory pathways improves interleukin-15 therapy.
Carson
William E
WE
Ohio State University Comprehensive Cancer Center, The Ohio State University, Columbus, Ohio 43210-1228, USA. william.carson@osumc.edu
D000818:Animals; D057134:Antibodies, Neutralizing / Q000008:administration & dosage / Q000494:pharmacology*; D015703:Antigens, CD / Q000276:immunology / Q000378:metabolism / Q000502:physiology; D000943:Antigens, Differentiation / Q000276:immunology / Q000378:metabolism / Q000502:physiology; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D060908:CTLA-4 Antigen; D045744:Cell Line, Tumor; D004195:Disease Models, Animal; D004353:Drug Evaluation, Preclinical; D004357:Drug Synergism; D007108:Immune Tolerance / Q000187:drug effects* / Q000276:immunology; D007167:Immunotherapy / Q000379:methods; D019409:Interleukin-15 / Q000627:therapeutic use*; D051379:Mice; D008954:Models, Biological; D009362:Neoplasm Metastasis; D009369:Neoplasms / Q000188:drug therapy* / Q000276:immunology / Q000401:mortality / Q000473:pathology; D061026:Programmed Cell Death 1 Receptor; D015398:Signal Transduction / Q000187:drug effects / Q000276:immunology; D016896:Treatment Outcome
D057134:Antibodies, Neutralizing; D015703:Antigens, CD; D000943:Antigens, Differentiation; D060908:CTLA-4 Antigen; C556707:Ctla4 protein, mouse; D019409:Interleukin-15; C491383:Pdcd1 protein, mouse; D061026:Programmed Cell Death 1 Receptor